Research programme: muscarinic receptor antagonists - Dong-A ST

Drug Profile

Research programme: muscarinic receptor antagonists - Dong-A ST

Alternative Names: DA-8010

Latest Information Update: 19 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Dong-A ST
  • Class
  • Mechanism of Action Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Overactive bladder

Most Recent Events

  • 29 Jun 2016 Dong-A ST plans a phase I trial in Healthy volunteers in United Kingdom (PO) (NCT02821312)
  • 06 May 2016 Pharmacodynamics data from preclinical studies in Overactive bladder presented at the 111th Annual Meeting of the American Urological Association (AUA-2016)
  • 09 Oct 2015 Research programme: muscarinic receptor antagonists - Dong-A ST is available for licensing -
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top